Funding sources This work was commissioned by the British Association of Dermatologists and the Department of Health.
A structured review of patient-reported outcome measures for patients with skin cancer, 2013
Article first published online: 5 JUN 2013
© The Authors BJD © 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 168, Issue 6, pages 1176–1186, June 2013
How to Cite
Gibbons, E., Casañas i Comabella, C. and Fitzpatrick, R. (2013), A structured review of patient-reported outcome measures for patients with skin cancer, 2013. British Journal of Dermatology, 168: 1176–1186. doi: 10.1111/bjd.12310
Conflicts of interest None declared.
- Issue published online: 5 JUN 2013
- Article first published online: 5 JUN 2013
- Accepted manuscript online: 14 MAR 2013 09:52AM EST
- Manuscript Accepted: 7 MAR 2013
The collection of patient-reported outcome measures (PROMs) within the national PROMs programme for elective procedures is now established mandatory practice in the NHS with high response rates and completion.
This review examines the evidence of PROMs for people with skin cancer.
Comprehensive searches were conducted using several sources and databases, using a detailed search strategy developed by the University of Oxford's PROM Group. Articles were assessed for eligibility. Data were extracted per PROM for each measurement property and appraised using an appraisal framework.
A total of 3517 articles were identified in the searches, and 28 were included in the final review after assessment by two independent reviewers. Two generic instruments (SF-36 and Sickness Impact Profile) and nine condition-specific PROMs were identified.
Overall, there is a limited volume of published evidence for the application of generic PROMs for people with skin cancer. Evaluation of the EQ-5D may be particularly important given its widespread use in many other healthcare contexts in the U.K. The Skin Cancer Index could be considered for piloting in the NHS. For patients with nonmelanoma skin cancers, the Skindex measures may also be considered. The SCQOLIT has some evidence of applicability across both skin cancer types but more evaluations are needed. The FACT-M does have more promising characteristics for patients with malignant melanomas although no evidence of testing in the U.K. was found. The forthcoming EORTC-M may prove a useful measure given the expertise and track record of this European collaboration in cancer and quality of life.